Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients

Exclusion Criteria

• •Any injection of the vaccine against Hepatitis B in the medical history
• •Acute cytolysis in the last 3 months with transaminases equal or above 5 times the upper normal range for HIV-HCV coinfected patients, or transaminases equal or above 2 times the upper normal for non coinfected patients
• •Any vaccine received one month before the inclusion
• •History of intolerance to any component of GenHevac-B
• •Evolutive opportunistic infection treated the month before the screening visit
• •Severe and acute pyretic infection or unexplained fever the week before inclusion
• •Evolutive hemopathy or solid-organ cancer
• •Prothrombin factor equal or below 50 percent and/or platelets equal or below 50 000 per mm3
• •Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg per day during above 7 days) in the last 6 months before the screening visit
• •Previous Immunomodulating treatment (interferon, interleukin-2,etc) or plan in the next 6 months
• •Splenectomy
• •Decompensated cirrhosis (Child Pugh B or C)
• •Kidney deficient function (creatinine clearance below 50 ml per mn)
• •Other immunocompromised condition not related to HIV infection (solid-organ transplantation, chemotherapy in the last 6 months)
• •Any participation to another clinical trial plan until Week 28